DeepMed Research

Diosmin

Generic Name: Diosmin

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₂O_₁₅

CAS Number: 520-27-4

Unique Ingredient Identifier: 7QM776WJ5N

Background: Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease.

Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.

Indication: Diosmin is used over-the-counter alone or with ingredients such as hesperidin and diosmetin to support vein and capillary function.

Associated Conditions: Capillary fragility, Circulatory Function, Haemorrhoids, Venous Insufficiency, Healthy capillaries, Healthy veins

Clinical Trials

Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Completed

Conditions: Pelvic Congestion Syndrome

Interventions: Drug: Daflon

First Posted Date: 2020-08-13

Last Posted Date: 2020-08-13

Lead Sponsor: Interregional Clinical Diagnostic Center, Russia

Target Recruit Count: 83

Registration Number: NCT04512443

Locations: 🇷🇺
Akhmetzianov Rustem, Kazan, Russian Federation
🇷🇺
Roman Bredikhin, Kazan, Russian Federation

Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome

Phase 4

Conditions: Pelvic Varices
Pelvic Congestive Syndrome
Venous Disease

Interventions: Device: Medtronic® Concerto® detachable coil system
Procedure: sclerosis
Drug: Diosmin / Hesperidin
Drug: Ibuprofen 400 mg

First Posted Date: 2020-04-24

Last Posted Date: 2020-04-24

Lead Sponsor: Hospital de Clínicas Dr. Manuel Quintela

Target Recruit Count: 120

Registration Number: NCT04358497

Clinical Non-inferiority Study Between Diosmin 600mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency

Phase 4

Completed

Conditions: Venous Insufficiency

Interventions: Drug: Diosmin / Hesperidin
Drug: Diosmin

First Posted Date: 2018-03-21

Last Posted Date: 2018-06-20

Lead Sponsor: Fundação Educacional Serra dos Órgãos

Target Recruit Count: 120

Registration Number: NCT03471910

Locations: 🇧🇷
Centro Universitário Serra dos Órgãos - UNIFESO, Teresópolis, RJ, Brazil

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis

Phase 4

Completed

Conditions: Postthrombotic Syndrome
Deep Vein Thrombosis

Interventions: Drug: Rivaroxaban
Drug: Diosmin
Other: compression stockings

First Posted Date: 2018-01-29

Last Posted Date: 2021-02-04

Lead Sponsor: Pirogov Russian National Research Medical University

Target Recruit Count: 90

Registration Number: NCT03413618

Locations: 🇷🇺
Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow, Russian Federation

Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD

Phase 1

Conditions: Menorrhagia

Interventions: Drug: Tranexamic Acid
Drug: Diosmin

First Posted Date: 2015-11-30

Last Posted Date: 2015-11-30

Lead Sponsor: Ain Shams University

Target Recruit Count: 100

Registration Number: NCT02616731

Locations: 🇪🇬
Ahmed Alanwar, Cairo, Egypt

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Diosmin
Drug: Cabergoline

First Posted Date: 2014-05-09

Last Posted Date: 2016-02-02

Lead Sponsor: Benha University

Target Recruit Count: 200

Registration Number: NCT02134249

Locations: 🇪🇬
Benha univesity hospital, Benha, El Qualyobia, Egypt
🇪🇬
Banha Universty, Banha, El Qalubia, Egypt

Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs

Phase 3

Completed

Conditions: Chronic Venous Disease of Lower Limbs

Interventions: Drug: Diosmin
Drug: Placebo

First Posted Date: 2012-02-15

Last Posted Date: 2013-04-29

Lead Sponsor: Laboratoire Innotech International

Target Recruit Count: 378

Registration Number: NCT01532882

Locations: 🇫🇷
Dr Jean-Jérôme GUEX, Nice, France

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

Phase 3

Conditions: Chronic Venous Insufficiency
Disease

Interventions: Drug: Daflon
Drug: Venaflon (Diosmin and Hesperidin)

First Posted Date: 2011-11-22

Last Posted Date: 2011-11-22

Lead Sponsor: Laboratório Teuto Brasileiro S/A

Target Recruit Count: 82

Registration Number: NCT01477281

Efficacy and Tolerability of the Use of Varicell Compared With Daflon

Phase 3

Conditions: Chronic Venous Insufficiency
Hemorrhoids

Interventions: Drug: Daflon
Drug: Varicell placebo

First Posted Date: 2011-03-23

Last Posted Date: 2011-06-14

Lead Sponsor: Vidfarma Indústria de Medicamentos Ltda.

Target Recruit Count: 102

Registration Number: NCT01321619

Locations: 🇧🇷
Santa Marcelina Hospital, São Paulo, Brazil

Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)

Phase 3

Conditions: Venous Insufficiency

Interventions: Drug: Flavonid
Drug: Daflon

First Posted Date: 2010-04-26

Last Posted Date: 2010-10-27

Lead Sponsor: Azidus Brasil

Target Recruit Count: 140

Registration Number: NCT01110512

Locations: 🇧🇷
Lal Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, SP, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy